Strategic innovation program Swelife
From the very onset, STUNS and Uppsala BIO were highly active in setting up and leading what later emerged as Swelife.
After the decision of St Jude Medical (2011) and AstraZeneca (2012) to shut down their R&D operations in Järfälla and Södertälje respectively, various actors in the national public sector met and analysed whether they could join forces to carry out missions to boost the country and thereby the region as well. This led to the establishment of the Strategic Innovation Agenda (SIO) ‘Sweden as an International Center for Life Science’ (SILS) initiative. When SILS started up in the summer of 2012, STUNS and Uppsala BIO were highly active from the onset.
In the spring 2014, SILS merged with another SIO focused on common diseases and was thereby granted support as the first Swedish Strategic Innovation Program (SIP) within life science. This name was later changed to Swelife. Uppsala BIO and STUNS had thus played an important role during more than two years of national coordination. Since 2014, Uppsala BIO has occupied a seat on the Governing Board of Swelife and been active in its operational leadership team.
Financing: Uppsala BIO* / Swelife (Case ID.: 2015-0724, 2017-05487)
Project duration: 2012–
Contact: Erik Forsberg, Uppsala BIO, Per Lundequist, STUNS
BIO’s and STUNS’ role: Deputy Process Leader SILS, Member of the Governing Boards SIO Common Diseases and Swelife
* Uppsala BIO’s core funding comes from the regional financiers Region Uppsala, SLU, Uppsala University and Uppsala Municipality, as well as from VINNVÄXT, a Vinnova-funded initiative.
Per Lundeqvist, STUNS